Company Overview
Corcept Therapeutics Incorporated is a biopharmaceutical entity focused on the discovery and development of medications designed to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders within the United States. Operating within the Healthcare sector and specifically the Biotechnology industry, the company leverages scientific research to create proprietary therapies for complex medical conditions that often require targeted pharmacological interventions. The company currently holds a market capitalization of $3.63B and generates annual revenue of $761.41M while employing a workforce of 730 individuals. These financial figures indicate that Corcept maintains a significant valuation relative to its revenue base, suggesting a market assessment that places a high premium on its pipeline assets and intellectual property rather than relying solely on current cash flow generation. The scale of operations, supported by a substantial market cap, reflects investor confidence in the potential of its therapeutic portfolio to address significant unmet medical needs in the specified disease areas.
Financial Health
The company reported revenue of $761.41M over the trailing twelve months, with a net income of $98.17M and EBITDA standing at $45.95M. The substantial gap between the $761.41M revenue and the $98.17M net income reveals a cost structure where operating expenses, likely driven by research and development costs typical of the biotechnology industry, absorb a significant portion of top-line growth before reaching the bottom line. Despite lower EBITDA, the company generated free cash flow of $114.19M, which provides a robust foundation for financial flexibility, allowing management to fund operations, pursue strategic acquisitions, or invest in clinical trials without immediate reliance on external equity financing. Profitability is highlighted by a gross margin of 98.3%, indicating highly efficient production of pharmaceutical products, while an operating margin of 2.2% and a profit margin of 13.1% demonstrate the impact of high fixed costs and R&D expenditures on overall profitability. The balance sheet appears conservative, holding $372.15M in cash against minimal debt of $6.11M, a disparity further confirmed by a debt-to-equity ratio of 0.94 which suggests low leverage relative to shareholder equity. Liquidity is strong with a current ratio of 2.92, indicating that the company possesses nearly three times the current assets necessary to cover its short-term liabilities. Management effectiveness is evidenced by a return on equity of 15.0% and a return on assets of 3.3%, showing that the company generates substantial returns on shareholder capital relative to the total asset base.
Valuation Assessment
Corcept trades with a trailing P/E ratio of 41.56 and a forward P/E of 21.19, where the significant difference between these metrics implies that the market expects earnings to grow substantially in the future to justify the current high multiple. The price-to-book ratio stands at 5.58, indicating that the market values the company at a heavy premium over its book value, likely due to the intangible value of its drug pipeline and intellectual property. Alternative valuation metrics such as a price-to-sales ratio of 4.76 and an EV/EBITDA of 70.94 suggest that investors are pricing the company based on growth potential and asset quality rather than current earnings power. The stock's price range over the past year spans from a low of $28.66 to a high of $117.33, providing a context for recent trading levels relative to historical volatility. The beta of 0.31 indicates that the stock's price volatility is significantly lower than the broader market, suggesting a defensive characteristic often found in biotechnology firms with established cash positions. These valuation multiples, particularly the forward P/E, suggest that the market anticipates a correction in costs or an acceleration in earnings to bring the multiple in line with historical averages.
Growth & Income
Revenue growth over the trailing twelve months reached 11.1%, while earnings growth was negative at -21.6%, indicating that earnings are currently growing slower than revenue due to likely fluctuations in operating expenses or one-time charges affecting the bottom line. As a non-dividend payer, Corcept does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all earnings back into research, development, and commercialization efforts rather than paying dividends. This reinvestment strategy is standard for biotechnology companies in the growth phase, where capital allocation towards expanding the product portfolio is prioritized over income generation for investors. The overall growth and income profile reflects a company in a high-growth, low-income distribution stage, where capital efficiency and pipeline progression are the primary drivers of shareholder value appreciation.